Pathway Bioventures: A seed-stage life sciences fund investing in innovative biotech for unmet medical needs.
3
Operating
2018
Chicago, IL, US
Pathway Bioventures is a Chicago-based life sciences venture fund founded by Daniel Jacobs, a cancer researcher with a PhD and MPH from Yale University. The firm invests in early-stage precision therapeutics companies working in genetic medicine and targeted therapies, backing entrepreneurs addressing significant unmet medical needs.
The fund participates in seed and Series A financing syndicates alongside investors including ARCH Venture Partners, Venrock, and Forbion, and supports portfolio teams with subsequent financings and introductions to future investors and partners. Its investments include Airna, Cytovale, Ochre Bio, miRecule, and Simergent.
Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies9
Follow-on Investments1
Current Portfolio Count8
Total Portfolio Exits1
Top Investment Stages
Seed5 (55.6%)
Series A3 (33.3%)
Pre-Seed1 (11.1%)
Stage Mix
Seed 56%Series A 33%Pre-Seed 11%
Concentration shown as share of disclosed investments by stage.